CYC065-eribulin combination for triple-negative breast cancer identified
Researchers find novel combination disrupts multiple factors in aggressive breast cancer...
List view / Grid view
Researchers find novel combination disrupts multiple factors in aggressive breast cancer...
Investigational therapy directly kills tumour cells and unmasks them to the body's defences.
Pregnancy-associated breast cancer, which is rare but often aggressive, has been detected with MRI...
Mvasi, a biosimilar to the cancer drug Avastin, is approved for certain colorectal, lung, brain, kidney and cervical cancers…
According to results of the LORELEI clinical trial, adding taselisib to letrozole before surgery significantly improved outcomes for patients with early breast cancer...
Z-endoxifen, a potent derivative of the drug tamoxifen, could itself be a new treatment for the most common form of breast cancer...
Researchers have recently discovered an immunotherapy that uses existing cancer drugs in a whole new way...
Scientists have developed a method to efficiently modify natural antibodies that can deliver drugs to target cells...
Novartis announced that the European Commission approved ribociclib in combination with an aromatase inhibitor for treatment of postmenopausal women with metastatic breast cancer
A clinical trial to test a new cancer drug in patients with advanced solid tumours, launches in four centres across the UK...
Researchers have developed a new imaging technique to detect myeloid-derived suppressor cells’ accumulating in the lung...
A new deal on the breast cancer drug trastuzumab emtansine means that it can now be recommended for routine funding.
The Scottish Medicines Consortium (SMC) has made a final decision to turn down Perjeta (pertuzumab) for routine NHS funding for first line use in women whose HER2-positive breast cancer has returned to the breast but is inoperable, or where it has spread to other parts of the body.
Q BioMed Inc has initiated production of Strontium-89 Chloride, a radiopharmaceutical indicated for the analgesic treatment of metastatic breast and prostate cancer bone pain.
8 June 2017 | By Niamh Marriott, Junior Editor
AstraZeneca's positive results from its trial that showed a statistically-significant and clinically-meaningful improvement in progression-free survival...